Pulmonology Medical News about Asthma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderate-Severe Allergic Asthma
Clinical Pediatrics, 09/18/09

Massanari M et al. – Omalizumab added to baseline therapy improves measures of asthma control in adolescents with persistent moderate–severe allergic asthma.

Exclusive Author Commentary
M. Massanari, 10/09/09

Achieving control of asthma is often difficult, particularly among adolescent patients with moderate-severe disease . Serum IgE plays an important role in the allergic asthma cascade. Addition of omalizumab, a humanized monoclonal anti-IgE antibody, to inhaled corticosteroids improves asthma control by reducing exacerbations and improving symptoms.

<< Previous
New Paradigms in the Pathogenesis of Chronic Obstructive...

Next >>
Fractional exhaled nitric oxide measurements are most closely...